Scientific Sessions 2025  /  Annual Lipid Update 2025  /  Will CETP inhibition PREVAIL in CVD prevention?
Logo

American Heart Association

  41
  0

Final ID:

Will CETP inhibition PREVAIL in CVD prevention?

  • Nicholls, Stephen  ( Victorian Heart Hospital , Clayton , Victoria , Australia )
    • Author Disclosures:
    Stephen Nicholls: DO have relevant financial relationships ; Researcher:AstraZeneca, NewAmsterdam Pharma, Amgen, Anthera, Cyclarity, Eli Lilly, Esperion, Novartis, Cerenis, The Medicines Company, Resverlogix, InfraReDx, Roche, Sanofi-Regeneron, and LipoScience:Active (exists now) ; Consultant:Abcentra, AstraZeneca, Amarin, Akcea, Eli Lilly, Anthera, Omthera, Merck, Takeda, Resverlogix, Sanofi-Regeneron, CSL Behring, Esperion, Boehringer Ingelheim, Daiichi Sankyo, Scribe Therapeutics, Silence Therapeutics, CSL Seqirus and Vaxxinity:Active (exists now)
Meeting Info:

Scientific Sessions 2025

2025

New Orleans, Louisiana

Session Info:

Annual Lipid Update 2025

Sunday, 11/09/2025 , 09:45AM - 11:00AM

Cardiovascular Seminar

More abstracts on this topic:
Will apoCIII therapies tip the BALANCE towards targeting triglycerides?

Tsimikas Sotirios, Ballantyne Christie

What LDL-C (or ApoB) level should we be targeting? And how ASCVD history inform LDL-C targets?

Khera Amit, Joshi Parag

More abstracts from these authors:
CRISPR-Cas9 Gene Editing Therapy Targeting ANGPTL3

Nicholls Stephen

Will dual GIP and GLP1 receptor agonism SURPASS existing GLP1RAs?

Sattar Naveed, Nicholls Stephen

You have to be authorized to contact abstract author. Please, Login
Not Available